Excellent
Mostly Aligned
Patient Risk:
Low
Summary
All evaluated themes are directly supported by the Eliquis US Prescribing Information excerpts provided (Boxed Warning on premature discontinuation and neuraxial/spinal/epidural hematoma, plus related Warnings and Precautions and interruption guidance).
Category Scores
Accurate Statements
Risks/warnings related to anticoagulant use with interruption and neuraxial anesthesia, including thrombotic risk after premature discontinuation and risk of spinal/epidural hematoma with neuraxial anesthesia/puncture.
Boxed Warning (A) and (B); Warnings and Precautions (5.1) and (5.3).
Temporary interruption guidance prior to invasive procedures based on bleeding risk; restart after adequate hemostasis established.
Dosage and Administration (2.4).
Risk of neuraxial/spinal/epidural hematoma may increase with concomitant medicinal products affecting hemostasis.
Boxed Warning (B) (and consistent with Warnings and Precautions (5.3) excerpt).
Unsupported Statements
None identified as stated beyond the provided label-supported themes.
All substantive risk/warning elements referenced in the evaluation are supported by the provided label excerpts.
Contradictions
Important Omissions
Specific operational details from Warnings and Precautions (5.3) regarding catheter removal timing (24 hours after last dose; next dose no earlier than 5 hours after removal) and timing/delay if traumatic puncture occurs (48 hours).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The evaluated claims concern boxed-warning level risks and are consistent with the provided label text; omissions relate to procedural timing specifics rather than reversing or denying the risks.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Missing label-specific neuraxial timing/catheter-removal and traumatic puncture delay details from Warnings and Precautions (5.3).
Suggested Improvement
Include the label’s specific timing guidance for catheter removal and subsequent dosing (and traumatic puncture delay) when describing neuraxial-associated risks.